Artiva Biotherapeutics (ARTV) Files IPO Registration Statement

Artiva Biotherapeutics (NASDAQ: ARTV) has filed for a proposed IPO.

The company describes itself as: "Our mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established Manufacturing-First approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies. Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkins lymphoma (NHL). We are also developing AB-201 and AB-202, our first two chimeric antigen receptor-NK (CAR-NK) product candidates. We plan to submit an investigational new drug application (IND) for AB-201 in the second half of 2022 and for AB-202 in 2023. We are leveraging our proprietary platform and manufacturing capabilities to generate a broad pipeline of off-the-shelf NK cell therapeutic candidates for the treatment of hematologic malignancies and solid tumors.

We believe our Manufacturing-First approach positions us to supplant the patient-specific business model for autologous cell therapy by delivering high quality campaign-manufactured products with low cost of goods and off-the-shelf-availability at the point of care. We accomplish this by optimizing the sourcing and selection of healthy donor umbilical cord blood; utilizing a highly scaled proprietary NK cell expansion and cryopreservation process; and leveraging an established manufacturing infrastructure and cold chain logistics. Today, we have the capability to manufacture thousands of doses of allogeneic NK cell drug product from a single cord blood unit, cryopreserve the NK cell doses in an infusion-ready solution, store the product with long-term shelf life while retaining activity and viability, and deliver the product to the clinic for administration of repeat dosing in an out-patient setting."

Goldman Sachs & Co. LLC, Cowen and Evercore ISI will serve as lead underwriters.

You May Also Be Interested In

• SK hynix files for Nasdaq IPO under ticker symbol SKHY
• Chemours reaches $450M settlement over PFAS pollution at four sites
• Goldman Sachs Downgrades Inspur Electronic Information Industry Co Ltd (000977:CH) to Sell